TICKERNERD
Menu
CBUSCBUSHealthcare · Biotechnology

CBUS Stock Forecast: Cibus, Inc. Price Predictions for 2026-2027

Last close, 8 Oct 2026
$1.59
−1.85% on the day

The 3 Wall Street analysts covering Cibus, Inc. hold a median 12-month price target of $16 — +906.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 42 of 100 as at 8 Oct 2026 — in the lower half.

Market cap
$121.5M
Ticker Nerd rank
42 / 100
Median analyst target
$16
Analysts covering
3
Revenue$994K+6.5% y/y
Operating income−$12.9M
Net income−$22.1M
Free cash flow−$9.4M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−2.5%
1M
−1.2%
YTD
−8.6%
1Y
+8.2%
From 52W high
−60.7%
From 52W low
+37.1%
$1.16
$4.05
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

CBUS stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Cibus, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 8 Oct 2026
42 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
88
Growth
74
Size
73
Momentum
62
Revisions
57
Quality
35
Volatility
12
Value
11
Issuance
8

Accruals (88): Reported profit is backed by cash, and the company is not expanding recklessly.

Issuance (8): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

CBUS stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CBUS, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$5.00$10.00$15.00$20.00$25.00Jan 26Apr 26Jul 26Oct 26CBUSHigh $25Median $16Low $2

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says3 analysts
2 Buy1 Hold0 Sell
Low $2Median $16High $25

The green dot is the last close — the median target sits +906.3% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
25 Mar 2026JefferiesMaintainsHold$1.90 → $3.00
8 Dec 2025Canaccord GenuityMaintainsBuy—
12 May 2025Canaccord GenuityMaintainsBuy—
21 Mar 2025HC Wainwright & Co.ReiteratesBuy—
22 Jan 2025Canaccord GenuityMaintainsBuy—
11 Nov 2024HC Wainwright & Co.ReiteratesBuy—
22 Oct 2024Canaccord GenuityMaintainsBuy—
24 Sept 2024Alliance Global PartnersMaintainsBuy—
19 Sept 2024Canaccord GenuityMaintainsBuy—
12 Aug 2024Canaccord GenuityMaintainsBuy—
29 July 2024Alliance Global PartnersInitiatesBuy—
19 July 2024Canaccord GenuityAssumesBuy$22
10 May 2024HC Wainwright & Co.ReiteratesBuy—
22 Mar 2024HC Wainwright & Co.MaintainsBuy—
9 Oct 2023HC Wainwright & Co.ReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CBUS appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

CBUS vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 8 Oct 2026, Cibus, Inc. returned +8.2% against +16.2% for the S&P 500, dividends included.

CBUS vs S&P 500, last 12 monthsTotal return, rebased to 100
100150200250300Jan 26Apr 26Jul 26Oct 26CBUSS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

CBUS analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
1
Fundamentals

Cibus, Inc. (CBUS) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−0.6×

Cheaper than 81% of US stocks

Price / sales
28.0×

Cheaper than 8% of US stocks

Price / book
8.2×

Cheaper than 12% of US stocks

EV / EBITDA
−8.0×

Cheaper than 83% of US stocks

Growth & margins
Revenue growth (YoY)
6.5%

Higher than 43% of US stocks

Earnings growth (YoY)
6.5%

Higher than 43% of US stocks

Gross margin
—
Operating margin
−1300.3%

Higher than 5% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−223.2%

Higher than 7% of US stocks

Return on assets
−10.2%

Higher than 26% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Cibus, Inc. (CBUS) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Cibus, Inc. has a market value of $121.5M and an enterprise value of $389.6M.

  • Revenue in the twelve months to 30 June 2026: $4.3M. The latest quarter grew 6.5% year on year.

  • Net income over the same four quarters: −$99.6M, a −2291.6% net margin.

  • Diluted earnings per share, trailing twelve months: $−1.65.

  • Free cash flow in the twelve months to 30 June 2026: −$46.3M.

  • Shares outstanding: 76.4M.

  • Trailing P/E: −0.6×; forward P/E: −2.5× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Cibus, Inc. employs 118 people — $37K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 9 Oct 2026

Data provided by Twelve Data

Peers

CBUS vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
CBUSCibus, Inc.$121.5M
42
NRXPNRX Pharmaceuticals, Inc.$121.2M
18
HUMAHumacyte, Inc.$120.6M
18
SEERSeer, Inc. (California)$122.1M
75
VTVTvTv Therapeutics, Inc.$118.5M
77
TNYATenaya Therapeutics, Inc.$117.8M
32
TNXPTonix Pharmaceuticals Holding Corp.$124.9M
30

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Cibus, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest CBUS news & analysis

Cibus and Crystal Crop Protection Team Up to Improve India's Mustard Crop

GlobeNewsWire · 28 Sept 2026positive

Cibus announced a collaboration with Crystal Crop Protection to combine its gene-editing platform with Crystal Crop's mustard varieties and distribution reach in India, aiming to deliver improved mustard seed to growers faster than conventional breeding.

Why it matters — This expands Cibus' gene-editing technology into the Indian mustard market through an established local partner, broadening its commercial footprint beyond its existing crops.

Cibus, Inc. (CBUS) Q2 2026 Earnings Call Transcript

Seeking Alpha · 14 Aug 2026neutral

The Seeking Alpha excerpt reports that the transcript of Cibus, Inc.'s (CBUS) second-quarter 2026 earnings call has been published. The provided text contains only the headline and the source attribution, indicating the call took place but offering no additional detail about its content.

Why it matters — The earnings call transcript gives CBUS watchers direct access to management's discussion of the company's second-quarter results and business outlook.

Cibus (CBUS) Reports Q2 Loss, Misses Revenue Estimates

Zacks Investment Research · 13 Aug 2026negative

Cibus reported a quarterly loss of $0.29 per share, which was wider than the Zacks Consensus Estimate of a $0.26 loss and missed revenue estimates. The loss narrowed from $0.61 per share in the same quarter a year ago.

Why it matters — The report shows the company's results fell short of analyst expectations, even though its per-share loss improved versus the prior year.

Cibus Q2 Earnings Call Highlights

MarketBeat · 13 Aug 2026neutral

Cibus reported second-quarter 2026 revenue of $1.0 million, up from $0.9 million a year earlier. The agricultural biotechnology company said it is advancing its Sustainable Ingredients program and updated the expected timing of its initial rice launch in Latin America.

Why it matters — CBUS watchers would care because the earnings update provides current revenue figures and signals progress on the company's Sustainable Ingredients program and Latin American rice launch timing.

Cibus Reports Second Quarter Financial Results and Provides Business Update

GlobeNewsWire · 13 Aug 2026positive

Cibus announced its Q2 2026 financial results, noting progress in commercialization for Rice and Sustainable Ingredients, regulatory alignment between the US and EU on treating crops without foreign DNA as conventionally bred, and a decline in quarterly net cash usage of 19% sequentially and 31% year over year.

Why it matters — A CBUS watcher would care because the company is advancing commercialization in key segments, achieving regulatory alignment in major markets, and improving its cash efficiency.

FAQ

Frequently asked questions about CBUS stock

What is the CBUS stock price forecast for 2026-2027?

The 3 Wall Street analysts covering Cibus, Inc. have a median 12-month price target of $16, with estimates ranging from $2 to $25. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is CBUS stock a buy right now?

Of the 3 analysts covering Cibus, Inc., 2 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Cibus, Inc. 42 out of 100 across roughly 4,600 US stocks as at 8 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank CBUS?

As at 8 Oct 2026, Cibus, Inc. ranks 42 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (88 of 100).

Will CBUS stock go up?

No one can know that. What the data says: the median 12-month target from 3 analysts implies +906.3% from the last close, and Ticker Nerd's factor model ranks Cibus, Inc. 42 out of 100 as at 8 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the CBUS stock forecast for 2030?

No analyst covering Cibus, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CBUS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $2 to $25 over the next 12 months.

How has CBUS stock performed over the past year?

Cibus, Inc. returned +8.2% over the 12 months to 8 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Cibus, Inc. do?

Cibus Inc. Class A Common Stock represents ownership in Cibus Inc., an agricultural biotechnology company based in San Diego, California.

What is the latest news on CBUS?

The most recent item we track (GlobeNewsWire, 28 Sept 2026): "Cibus and Crystal Crop Protection Team Up to Improve India's Mustard Crop". Cibus announced a collaboration with Crystal Crop Protection to combine its gene-editing platform with Crystal Crop's mustard varieties and distribution reach in India, aiming to deliver improved mustard seed to growers faster than conventional breeding.

Company

About Cibus, Inc.

Cibus Inc. Class A Common Stock represents ownership in Cibus Inc., an agricultural biotechnology company based in San Diego, California. The company develops and licenses gene-edited plant traits for seed companies, using proprietary technologies to improve crop productivity, resilience, and sustainability. Its work centers on traits that can help address challenges such as yield performance, disease pressure, weed control, nutrient use, and climate stress across major crops including canola, rice, soybean, corn, and wheat. Cibus also develops plant traits for sustainable ingredients and other agricultural applications that support lower-input farming and more efficient production systems. As a publicly traded equity security, Cibus Inc. Class A Common Stock provides market participants with exposure to a company focused on agricultural innovation, crop trait development, and commercial licensing within the biotechnology sector.

CEO Dr. Peter R. Beetham B.Sc., Ph.D. · 118 employees · United States · https://www.cibus.com